DOCSLIB.ORG

Characterization of Hyperinsulinism in Infancy Assessed with PET and 18F-Fluoro-L-DOPA

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Characterization of Hyperinsulinism in Infancy Assessed with PET and 18F-Fluoro-L-DOPA Characterization of Hyperinsulinism in Infancy Assessed with PET and 18F-Fluoro-L-DOPA Maria-Joa˜o Ribeiro, MD, PhD1; Pascale De Lonlay, MD, PhD2; Thierry Delzescaux, PhD1; Nathalie Boddaert, MD3; Francis Jaubert, MD4; Sandrine Bourgeois1; Fre´de´ric Dolle´, PhD1; Claire Nihoul-Fe´ke´te´, MD5; Andre´ Syrota, MD, PhD1; and Francis Brunelle, MD3 1Service Hospitalier Fre´de´ric Joliot, De´partement de Recherche Me´dicale, Direction des Sciences du Vivant, Commissariat a` l’Energie Atomique, Orsay, France; 2De´partement de Me´tabolisme et Pe´diatrie, Hoˆpital Necker-Enfants Malades, Paris, France; 3Service de Radiologie Pe´diatrique, Hoˆpital Necker-Enfants Malades, Paris, France; 4Laboratoire de Anatomopathologie, Hoˆpital Necker-Enfants Malades, Paris, France; and 5De´partement de Chirurgie Infantile, Hoˆpital Necker-Enfants Malades, Paris, France Hyperinsulinism (HI) of infancy is a neuroendocrine disease Hyperinsulinism (HI) is the most important cause of secondary to either focal adenomatous hyperplasia or a diffuse recurrent hypoglycemia in infancy. The hypersecretion of abnormality of insulin secretion of the pancreas. HI with focal insulin induces profound hypoglycemias that require ag- lesions can revert by selective surgical resection in contrast to gressive treatment to prevent the high risk of neurologic the diffuse form, which requires subtotal pancreatectomy when resistant to medical treatment. Neuroendocrine diseases are a complications (1,2). HI can be due to 2 different histopatho- heterogeneous group of entities with the ability to take up amine logic types of lesions, a focal or a diffuse form (3,4), based precursors and to convert them into biogenic amines. There- on different molecular entities despite an indistinguishable fore, the aim of this study was (a) to evaluate the use of PET with clinical pattern (5–9). In focal HI, which represents about 18F-fluoro-L-dihydroxyphenylalanine (18F-fluoro-L-DOPA) and (b) 40% of all cases (10), the pathologic pancreatic ␤-cells are to distinguish between focal and diffuse HI. Methods: Fifteen gathered in a focal adenoma, usually 2.5–7.5 mm in diam- patients (11 boys, 4 girls) with neonatal HI were enrolled in this eter. Conversely, diffuse HI corresponds to an abnormal study. All patients fasted for at least 6 h before the PET exam- insulin secretion of the whole pancreas with disseminated ination and their medication was discontinued for at least 72 h. ␤ The examination was performed under light sedation (pentobar- -cells showing enlarged abnormal nuclei (11). Finally, bital associated with or without chloral). The dynamic acquisi- about 10% of HI cases are clinically atypical and cannot be tion started 45–65 min after the injection of 18F-fluoro-L-DOPA classified, having an unknown molecular basis and his- (4.0 MBq/kg weight). Four or 6 scans of 5 min each (2 or 3 steps topathologic form (12). according to the height of the patient) were acquired from the Control of HI is attempted through medical treatment neck to the upper legs. Results: An abnormal focal pancreatic with diazoxide, nifedipine, or octreotide (13–15), but pan- uptake of 18F-fluoro-L-DOPA was observed in 5 patients, createctomy is the only issue for patients who are resistant whereas a diffuse uptake of the radiotracer was observed in the pancreatic area of the other patients. All patients with focal to these treatments (10,16). Therefore, the differential diag- radiotracer uptake and also 4 of 10 patients with pancreatic nosis between the 2 forms becomes of major importance diffuse radiotracer accumulation, unresponsive to medical treat- since their surgical treatment and the outcome differ con- ment, underwent surgery. The histopathologic results confirmed siderably. Focal HI is totally cured by selective resection of the PET findings—that is, focal versus diffuse HI. Conclusion: the adenoma, whereas diffuse forms of HI require a subtotal The results of this study suggest that 18F-fluoro-L-DOPA could pancreatectomy, with severe iatrogenic diabetes as a con- be an accurate noninvasive technique to distinguish between sequence (17,18). focal and diffuse forms of HI. The localization of insulin hypersecretion before surgery 18 Key Words: hyperinsulinism of infancy; PET; F-fluoro-L-DOPA is possible only through pancreatic venous catheterization J Nucl Med 2005; 46:560–566 (PVS), allowing a pancreatic map of insulin concentrations, with an eventual additional pancreatic arterial calcium stim- ulation (19–21). PVS is an invasive method, which is tech- nically difficult to perform and requires general anesthesia. The concentrations of plasmatic glucose must be maintained between 2 and 3 mmol/L before and during PVS. Moreover, Received Sep. 9, 2004; revision accepted Dec. 15, 2004. For correspondence or reprints contact: Maria-Joa˜ o Ribeiro, MD, PhD, all medical treatments must be stopped 5 d before the study. Service Hospitalier Fre´de´ ric Joliot, DRM/DSV, CEA, 4, place du Ge´ne´ ral Therefore, it is of major interest to find a less invasive way Leclerc, F-91406 Orsay, France. E-mail: [email protected] to differentiate between focal and diffuse HI. This method 560 THE JOURNAL OF NUCLEAR MEDICINE • Vol. 46 • No. 4 • April 2005 should precisely localize the pathologic area of focal HI to MATERIALS AND METHODS guide the surgeon. Patients L-Dihydroxyphenylalanine (L-DOPA) is a precursor of Fifteen patients (11 boys, 4 girls; age range, 1–14 mo; mean catecholamines that is converted to dopamine by the aro- age Ϯ SD, 5.7 Ϯ 3.8 mo) with neonatal HI were studied with matic amino acid decarboxylase (AADC). In addition to its 18F-fluoro-L-DOPA and PET (Table 1). In all cases, HI diagnosis role as a precursor of noradrenaline and adrenaline, dopa- was based on persistent hypoglycemia with low plasma ketone mine is a transmitter substance in the central and peripheral bodies and free fatty acids together with measurable circulating nervous system. The capacity to take up and decarboxylate insulin levels at the time of hypoglycemia. amine precursors such as L-DOPA and 5-hydroxytrypto- All patients fasted for at least 6 h before the PET study and their phan and to store their biogenic amine (dopamine and medications were stopped for at least 72 h. Two patients had 2 scans. One patient had a PET study before and after treatment with serotonin) is characteristic of neuroendocrine cells. an inhibitor of AADC (L-␣-hydrazino-␣-methyl-␤-(3,4-dihydroxy- Pancreatic cells contain markers usually associated with phenyl)propionic acid or carbidopa). Another patient had a PET neuroendocrine cells, such as tyrosine hydroxylase, dopa- study 72 h after drug withdrawal and another PET study after mine, neuronal dopamine transporter, vesicular dopamine administration of octreotide and diazoxide. During all PET studies, transporter, and monoamine oxidases A and B (22–24). normoglycemia was maintained by glucose infusion, which was Pancreatic islets have been shown to take up L-DOPA and carefully adjusted according to frequent blood glucose monitoring. convert it to dopamine through the AADC (25–27). Maximal glucose infusion rates between 6.4 and 13.2 mg/kg/min PET performed with 18F-fluoro-L-dihydroxyphenylala- were needed. PET acquisition was performed under light sedation nine (18F-fluoro-L-DOPA) has been extensively used to (pentobarbital associated with or without chloral). study the central dopaminergic system. Nevertheless, sev- The 5 patients for whom 18F-fluoro-L-DOPA uptake results eral recent studies have demonstrated the usefulness of this strongly suggested focal HI and the patients with diffuse HI ϭ radiotracer to detect neuroendocrine tumors such as pheo- resistant to medical treatment (n 4/10) underwent surgery. chromocytomas, thyroid medullar carcinomas, or gastroin- Pancreatic tissue obtained from surgical resections was fixed in formalin and embedded in paraffin, and serial sections were stud- testinal carcinoid tumors that usually contain secretory ied by immunohistochemistry after a water bath antigen retrieval granules and have the ability to produce biogenic amines step. The primary antibodies used were antiproinsulin (1/400 (28,29). mouse monoclonal antibody, 1G4; Novocastra), antichromogranin The aim of this work was to evaluate the use of whole- A (1/200 mouse monoclonal antibody DAK-A3; DAKO), antisyn- body PET with 18F-fluoro-L-DOPA to detect the hyperfunc- aptophysin (1/50 rabbit polyclonal antibody A0010; DAKO), and tional pancreatic islet tissue and to test its ability to differ- anti-DOPA decarboxylase or anti-AADC (1/100 rabbit polyclonal entiate between focal and diffuse HI. antibody; Chemicon International). TABLE 1 Clinical Profile of 15 Patients with HI Birth Age (mo) Weight at Patient weight Gestational At At PET PET scan Response to no. Sex (g) age (wk) diagnosis scan (g) medication Surgery 1 M 3,470 36 Neonatal 5 7,500 DzxϪ, OctrϪ Yes 2 M 3,760 40 Neonatal 3 5,800 DzxϪ, OctrϪ Yes 3 F 3,310 38 Neonatal 2 5,000 DzxϪ, OctrϪ Yes 4 M 3,871 38 Neonatal 4 9,160 DzxϪ, OctrϪ Yes 5 M 4,050 37 Neonatal 7 10,870 DzxϪ, Octrϩ Yes 6 M 4,450 38 Neonatal 4 8,190 DzxϪ, OctrϪ Yes 7 M 3,690 36 Neonatal 5 8,600 DzxϪ, Octrϩ No 8 M 3,900 39 Neonatal 3 and 12 6,800 DzxϪ, Octrϩ No 10,680 9 F 2,950 37 2.5 13 11,000 Dzxϩ No 10 F 4,010 37 Neonatal 8 7,300 DzxϪ, Octrϩ No 11 F 3,480 37 Neonatal 5 6,070 DzxϪ, OctrϪ Yes 12 M 5,000 38 Neonatal 14 and 17 11,500 DzxϪ, OctrϪ Yes 12,200 13 M 3,700 38 Neonatal 2 6,670 DzxϪ, Octrϩ No 14 M 3,800 38 Neonatal 9 9,800 DzxϪ, Octrϩ No 15 M 3,580 36 Neonatal 2 6,000 DzxϪ, OctrϪ Yes Dzx ϭ diazoxide; Octr ϭ octreotide. HYPERINSULINISM OF INFANCY AND PET • Ribeiro et al.
Load more

Recommended publications
  • Hyperinsulinemic Hypoglycemia in Infancy: Current Concepts in Diagnosis and Management
    RRR EEE VVV III EEE WWW AAA RRR TTT III CCC LLL EEE Hyperinsulinemic Hypoglycemia in Infancy: Current Concepts in Diagnosis and Management SHRENIK VORA, SURESH CHANDRAN, VICTOR SAMUEL RAJADURAI AND #KHALID HUSSAIN From Department of Neonatology, KK Women’s and Children’s Hospital, Singapore; and #Genetics and Epigenetics in Health and Disease Genetics and Genomic Medicine Programme, UCL Institute of Child Health, Great Ormond Street Hospital for Children, 30 Guilford Street, London, UK. Correspondence to: Dr Shrenik Vora, Senior Staff Registrar, Department of Neonatology, KK Women’s and Children’s Hospital, 100, Bukit Timah Road, Singapore 229899. [email protected] Purpose: Molecular basis of various forms of hyperinsulinemic hypoglycemia, involving defects in key genes regulating insulin secretion, are being increasingly reported. However, the management of medically unresponsive hyperinsulinism still remains a challenge as current facilities for genetic diagnosis and appropriate imaging are limited only to very few centers in the world. We aim to provide an overview of spectrum of clinical presentation, diagnosis and management of hyperinsulinism. Methods: We searched the Cochrane library, MEDLINE and EMBASE databases, and reference lists of identified studies. Conclusions: Analysis of blood samples, collected at the time of hypoglycemic episodes, for intermediary metabolites and hormones is critical for diagnosis and treatment. Increased awareness among clinicians about infants “at-risk” of hypoglycemia, and recent advances in genetic diagnosis have made remarkable contribution to the diagnosis and management of hyperinsulinism. Newer drugs like lanreotide (long acting somatostatin analogue) and sirolimus (mammalian target of rapamycin (mTOR) inhibitor) appears promising as patients with diffuse disease can be treated successfully without subtotal pancreatectomy, minimizing the long-term sequelae of diabetes and pancreatic insufficiency.
    [Show full text]
  • Mechanisms of Disease: Advances in Diagnosis and Treatment of Hyperinsulinism in Neonates Diva D De León and Charles a Stanley*
    REVIEW www.nature.com/clinicalpractice/endmet Mechanisms of Disease: advances in diagnosis and treatment of hyperinsulinism in neonates Diva D De León and Charles A Stanley* SUMMARY INTRODUCTION Etiology of neonatal hypoglycemia Hyperinsulinism is the single most common mechanism of hypoglycemia Hypoglycemia is a frequent problem in newborn in neonates. Dysregulated insulin secretion is responsible for the infants that must be diagnosed and treated effi- transient and prolonged forms of neonatal hypoglycemia, and congenital ciently to avoid seizures and permanent brain genetic disorders of insulin regulation represent the most common damage. Management is complicated by the fact of the permanent disorders of hypoglycemia. Mutations in at least five genes have been associated with congenital hyperinsulinism: they that neonates present a remarkably wide range of encode glucokinase, glutamate dehydrogenase, the mitochondrial possible causes for hypoglycemia. These include enzyme short-chain 3-hydroxyacyl-CoA dehydrogenase, and the two transient forms of hypoglycemia that can occur components (sulfonylurea receptor 1 and potassium inward rectifying in normal infants, more prolonged forms of channel, subfamily J, member 11) of the ATP-sensitive potassium hypoglycemia that are associated with compli- channels (K channels). K hyperinsulinism is the most common and cations of gestation and delivery, and neonatal ATP ATP presentation of permanent hypo glycemia severe form of congenital hyperinsulinism. Infants suffering from KATP hyperinsulinism present shortly after birth with severe and persistent dis orders due to endocrine or metabolic diseases hypoglycemia, and the majority are unresponsive to medical therapy, thus (Box 1). The risks of these various forms change requiring pancreatectomy. In up to 40–60% of the children with KATP hyperinsulinism, the defect is limited to a focal lesion in the pancreas.
    [Show full text]
  • Hypoglycemia Diagnosis and Management
    HYPOGLYCEMIA DIAGNOSIS AND MANAGEMENT Beckwith-Wiedemann syndrome (BWS) is a rare disorder involving changes on a region of chromosome 11p15 that influence pre- and postnatal growth. These changes disrupt the normal balance of growth gene expression and lead to the overgrowth seen in patients with BWS. Depending on which parts of the body are affected, children with BWS can have different features. These include overgrowth of the pancreas leading to hypoglycemia or hyperinsulinism. What is hypoglycemia? Hypoglycemia is low blood sugar. It is important for the body to have normal blood sugar levels because low sugar levels can cause problems including seizures and brain damage. Approximately half of infants with BWS will have hypoglycemia. In most of these children, hypoglycemia will only last for a few days and can easily be treated with frequent feedings and/or medical doses of sugar (dextrose infusions). However, in 5-10% of children with BWS, hypoglycemia can persist, requiring additional monitoring and medical care. What causes hypoglycemia in children with BWS? Although hypoglycemia can happen for many reasons, in children with BWS, it is usually caused when the pancreas makes too much insulin (hyperinsulinism). Insulin lowers blood sugar (also called glucose) levels. We suspect that low blood sugar levels in BWS have to do with the genes on chromosome 11p15 that control growth. Additionally, there are some other genes on chromosome 11 that affect how some of the cells in the pancreas work. How do we test for hypoglycemia? A normal blood sugar level is 70 – 120 mg/dL. Low glucose levels are common in the first 24 hours of life; after the second day of life, glucose levels should normalize.
    [Show full text]
  • Congenital Hyperinsulinism
    Winner of the Case of the Year SWISS SOCIETY OF NEONATOLOGY Award 2012 Congenital hyperinsulinism FEBRUARY 2012 2 Morgillo D, Berger TM, Caduff JH, Barthlen W, Mohnike K, Mohnike W, Neonatal and Pediatric Intensive Care Unit (MD, BTM), Department of Pediatric Radiology (CJH), Children‘s Hospital of Lucerne, Lucerne, Switzerland, Department of Pediatric Surgery, University Medicine Greifswald (BW), Greifswald, Germany, Department of Pediatrics, University Hospital of Magdeburg (MK), Magdeburg, Germany, Diagnostic Therapeutic Centre Frankfurter Tor (MW), Berlin, Germany © Swiss Society of Neonatology, Thomas M Berger, Webmaster 3 Congenital hyperinsulinism (CHI) is characterized by INTRODUCTION inappropriate secretion of insulin by the ß cells of the islets of Langerhans and is an extremely heterogene- ous condition in terms of clinical presentation, histo- logical subgroups and underlying molecular biology. Histologically, CHI has been classified into two major subgroups: diffuse (affecting the whole pancreas) and focal (being localized to a single region of the pancreas) disease. Advances in molecular genetics, radiological imaging techniques (such as fluorine-18 L-3,4-dihydroxyphenylalanine-PET-CT (18FDOPA-PET-CT) scanning) and surgical techniques have completely changed the clinical approach to infants with severe congenital forms of hyperinsulinemic hypoglycemia. This male infant was born to a healthy 35-year-old G3/P3 CASE REPORT by spontaneous vaginal delivery at 38 4/7 weeks. His birth weight was 3530 g (P 50-75), his head circum- ference was 35 cm (P 25) and his length was 50 cm (P 25-50). Postnatal adaptation was normal with an arterial cord pH of 7.28 and Apgar scores of 8, 9, and 9 at 1, 5, and 10 minutes, respectively.
    [Show full text]
  • Functional Imaging of Insulitis in Type 1 Diabetes
    FUNCTIONAL IMAGING OF INSULITIS IN TYPE 1 DIABETES Teemu Kalliokoski TURUN YLIOPISTON JULKAISUJA – ANNALES UNIVERSITATIS TURKUENSIS Sarja - ser. D osa - tom. 1135 | Medica - Odontologica | Turku 2014 University of Turku Faculty of Medicine Department of Clinical Medicine Pediatrics and Turku PET Centre Doctoral Programme of Clinical Investigation Supervised by Professor emeritus Olli Simell (MD, PhD) Adjunct professor Merja Haaparanta-Solin (MSc, PhD) University of Turku, Faculty of Medicine University of Turku, Faculty of Medicine Department of Pediatrics Turku PET Centre Reviewed by Professor Timo Otonkoski (MD, PhD) Docent Olof Eriksson (MSc, PhD) University of Helsinki Uppsala University Children’s Hospital Department of Medicinal Chemistry Opponent Professor Alberto Signore (MD, PhD) Sapienza University Nuclear Medicine Unit Rome, Italy The originality of this thesis has been checked in accordance with the University of Turku quality assurance system using the Turnitin OriginalityCheck service. ISBN 978-951-29-5859-7 (PRINT) ISBN 978-951-29-5860-3 (PDF) ISSN 0355-9483 Painosalama Oy - Turku, Finland 2014 Adjunct professor Merja Haaparanta-Solin (MSc, PhD) University of Turku, Faculty of Medicine Turku PET Centre To Mervi, and our children Elias and Iiris 4 Abstract ABSTRACT Teemu Kalliokoski FUNCTIONAL IMAGING OF INSULITIS IN TYPE 1 DIABETES Department of Pediatrics and Turku PET Centre, Faculty of Medicine, University of Turku Annales Universitatis Turkuensis, 2014, Turku, Finland Type 1 diabetes (T1D) is an immune-mediated disease characterized by autoimmune inflammation (insulitis), leading to destruction of insulin-producing pancreatic β-cells and consequent dependence on exogenous insulin. Current evidence suggests that T1D arises in genetically susceptible children who are exposed to poorly characterized environmental triggers.
    [Show full text]
  • Cell Death During Progression to Diabetes
    insight review articles b-Cell death during progression to diabetes Diane Mathis, Luis Vence & Christophe Benoist Section on Immunology and Immunogenetics, Joslin Diabetes Centre; Department of Medicine, Brigham and Women’s Hospital; Harvard Medical School, One Joslin Place, Boston, Massachusetts 02215, USA (e-mail: [email protected]) The hallmark of type 1 diabetes is specific destruction of pancreatic islet b-cells. Apoptosis of b-cells may be crucial at several points during disease progression, initiating leukocyte invasion of the islets and terminating the production of insulin in islet cells. b-Cell apoptosis may also be involved in the occasional evolution of type 2 into type 1 diabetes. ype 1 diabetes is an autoimmune disease sis of autoimmune diabetes. We do not know what triggers resulting from specific destruction of the it, have little understanding of the genetic and environmen- insulin-producing b-cells of the islets of tal factors regulating its progression, and have a confused Langerhans of the pancreas1. It has two distinct view of the final effector mechanism(s). Consequently, we phases: insulitis, when a mixed population of still do not know how to prevent or reverse type 1 diabetes in Tleukocytes invades the islets; and diabetes, when most a sufficiently innocuous manner to be therapeutically b-cells have been killed off, and there is no longer useful. Faced with the difficulties of addressing these issues sufficient insulin production to regulate blood glucose in humans, many investigators have turned to small-animal levels, resulting in hyperglycaemia. Individuals can have models of diabetes, in particular the non-obese diabetic covert insulitis for a long time (years in humans, months (NOD) mouse and transgenic derivatives of it (Box 1).
    [Show full text]
  • Diazoxide-Responsive Hyperinsulinism
    Diazoxide-responsive Hyperinsulinism Linda Boyajian , CRNP Diva D. De León-Crutchlow, MD, MSCE Congenital Hyperinsulinism Center The Children’s Hospital of Philadelphia Picture courtesy of Dr. Colin Hawkes Outline Definition of diazoxide-responsiveness Genetic mutations in diazoxide-responsive hyperinsulinism Treatment of diazoxide-unresponsive hyperinsulinism Diazoxide-responsiveness Able to wean intravenous dextrose Able to maintain normal plasma glucose during: . Normal feeding schedule . Overnight fast Diazoxide-Responsive HI • Common Genetic – GDH-HI (HI-HA Syndrome) – KATP-HI • Very common non-Genetic – Perinatal-Stress HI • Rarer Genetic – HNFs-HI Frequency of diazoxide-unresponsive hyperinsulinism FOCAL HI n = 207 (50%) SURGICAL DIFFUSE HI n = 415 n = 192 (46%) (92%) Diazoxide LINE HI Unresponsive n = 13 (3%) n = 451 (58%) NON- ATYPICAL SURGICAL n = 3 (1%) HI Panel ‡ n = 36 (8%) N = 782 Diazoxide Responsive n = 263 (34%) § ‡ = ABCC8, KCNJ11, GCK, GLUD1 § = add’l genes: HNF4A, HNF1A, HADH, UCP2 Syndromic-HI n = 68 (8%) Children with hyperinsulinism seen at CHOP between 1997-2015 Genotype of 705 children (1997-2014) 1 dom GLUD1 No mutations Focal (1 rec KATP) 1 dom KATP Diffuse (2 rec KATP) Diazoxide-Unresponsive Diazoxide-Responsive (434) (219) KATP-HI: the most common genetic form of hyperinsulinism • Caused by inactivating mutations of SUR1 or Kir6.2 (ABCC8, KCNJ11) on chromosome 11p • Four clinical types 1. Recessive mutations: Diffuse HI, severe neonatal onset hypoglycemia, diazoxide non-responsive 2. Focal adenomatosis: Focal HI; clinically indistinguishable from severe recessive KATP-HI; paternally-derived recessive KATP mutation PLUS maternal 11p LOH; curable by surgery(!) 3. Dominant mutations (severe): Diffuse HI, severe neonatal onset hypoglycemia, diazoxide non-responsive 4.
    [Show full text]
  • Congenital Hyperinsulinism
    Congenital hyperinsulinism Description Congenital hyperinsulinism is a condition that causes individuals to have abnormally high levels of insulin, which is a hormone that helps control blood sugar levels. People with this condition have frequent episodes of low blood sugar (hypoglycemia). In infants and young children, these episodes are characterized by a lack of energy (lethargy), irritability, or difficulty feeding. Repeated episodes of low blood sugar increase the risk for serious complications such as breathing difficulties, seizures, intellectual disability, vision loss, brain damage, and coma. The severity of congenital hyperinsulinism varies widely among affected individuals, even among members of the same family. About 60 percent of infants with this condition experience a hypoglycemic episode within the first month of life. Other affected children develop hypoglycemia by early childhood. Unlike typical episodes of hypoglycemia, which occur most often after periods without food (fasting) or after exercising, episodes of hypoglycemia in people with congenital hyperinsulinism can also occur after eating. Frequency Congenital hyperinsulinism affects approximately 1 in 50,000 newborns. This condition is more common in certain populations, affecting up to 1 in 2,500 newborns. Causes Congenital hyperinsulinism is caused by mutations in genes that regulate the release ( secretion) of insulin, which is produced by beta cells in the pancreas. Insulin clears excess sugar (in the form of glucose) from the bloodstream by passing glucose into cells to be used as energy. Gene mutations that cause congenital hyperinsulinism lead to over-secretion of insulin from beta cells. Normally, insulin is secreted in response to the amount of glucose in the bloodstream: when glucose levels rise, so does insulin secretion.
    [Show full text]
  • Stem Cells from Patients with Congenital Hyperinsulinism
    Stem cells from patients with Congenital Hyperinsulinism A thesis submitted to the University of Manchester for the degree of doctor of philosophy in the Faculty of Biology, Medicine and Health School of Medical Sciences Sophie Grace Kellaway 2016 Contents 0.1 Abbreviations . 9 0.2 Abstract . 11 0.3 Declaration . 12 0.4 Copyright statement . 12 0.5 Acknowledgements . 13 0.6 Thesis organisation . 14 0.7 Author note . 15 1 Literature Review 16 1.1 Introduction . 16 1.2 The Pancreas . 17 1.2.1 Anatomy . 17 1.2.2 Development . 20 1.2.3 Post developmental endocrine proliferation . 23 1.2.4 Cell cycle in the pancreas . 23 1.2.5 Signalling and markers . 25 1.3 Congenital hyperinsulinism (CHI) . 27 1.3.1 Symptoms and causes . 27 1.3.2 Hyperproliferation . 30 1.3.3 Treatment . 30 1.3.4 Experimental models . 30 1.4 Diabetes . 31 1.4.1 Epidemiology . 31 1.4.2 Pathogenesis . 32 1.4.3 Treatment . 33 1.5 Stem Cells . 34 1.5.1 Pancreatic stem cells . 34 1.5.2 Mesenchymal stem cells . 35 2 1.5.3 Pluripotent stem cells . 38 1.5.4 Generation of iPSCs . 41 1.6 Aims . 43 1.7 References . 43 2 A Novel Source of Mesenchymal Stem Cells derived from the Pancreas of Patients with Congenital Hyperinsulinism. 64 2.1 Abstract . 65 2.2 Introduction . 66 2.3 Methods . 68 2.3.1 Derivation of CHI pancreatic mesenchymal stem cell (CHI pMSC) lines . 68 2.3.2 Cell culture . 68 2.3.3 Karyotyping .
    [Show full text]
  • Glucokinase MODY Is the Most Prevalent Subtype Responsible for About 70% of Confirmed Cases
    life Article A Comprehensive Analysis of Hungarian MODY Patients—Part II: Glucokinase MODY Is the Most Prevalent Subtype Responsible for about 70% of Confirmed Cases Zsolt Gaál 1, Zsuzsanna Sz ˝ucs 2, Irén Kántor 3 , Andrea Luczay 4,Péter Tóth-Heyn 4, Orsolya Benn 5, Enik˝oFelszeghy 6, Zsuzsanna Karádi 5,László Madar 2 and István Balogh 2,* 1 4th Department of Medicine, Jósa András Teaching Hospital, 4400 Nyíregyháza, Hungary; [email protected] 2 Division of Clinical Genetics, Department of Laboratory Medicine, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary; [email protected] (Z.S.); [email protected] (L.M.) 3 Department of Pediatrics, Jósa András Teaching Hospital, 4400 Nyíregyháza, Hungary; [email protected] 4 1st Department of Pediatrics, Semmelweis University, 1085 Budapest, Hungary; [email protected] (A.L.); [email protected] (P.T.-H.) 5 Department of Pediatrics, Szent György Hospital of Fejér County, 8000 Székesfehérvár, Hungary; [email protected] (O.B.); [email protected] (Z.K.) 6 Department of Pediatrics, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary; [email protected] * Correspondence: [email protected] Citation: Gaál, Z.; Sz˝ucs,Z.; Kántor, I.; Luczay, A.; Tóth-Heyn, P.; Benn, O.; Abstract: MODY2 is caused by heterozygous inactivating mutations in the glucokinase (GCK) gene Felszeghy, E.; Karádi, Z.; Madar, L.; that result in persistent, stable and mild fasting hyperglycaemia (5.6–8.0 mmol/L, glycosylated Balogh, I. A Comprehensive Analysis haemoglobin range of 5.6–7.3%). Patients with GCK mutations usually do not require any drug of Hungarian MODY Patients—Part treatment, except during pregnancy.
    [Show full text]
  • Maternal Hyperglycaemia and Foetal Hyperinsulinism in Diabetic Pregnancy James W
    Postgrad Med J: first published as 10.1136/pgmj.38.445.612 on 1 November 1962. Downloaded from POSTGRAD. MED. J. (I962), 38, 6IZ MATERNAL HYPERGLYCAEMIA AND FOETAL HYPERINSULINISM IN DIABETIC PREGNANCY JAMES W. FARQUHAR, M.D., F.R.C.P.(Edin.) Department of Child Life and Health, University of Edinburgh; Simpson Memorial Maternity Pavilion, Royal Infirmary, Edinburgh THE babies born to diabetic women, and to those implied such retention of water that it made a women whose diabetes declares itself only in later significant contribution to the excessive birth life, are usually heavier than average for their weight, and that in shedding it as urine the infants gestational age, and their overall length may be lost much more than the usual amount of weight greater. They have a pronounced tendency to during the first week of life. The fact that Cardell develop brief neonatal hypoglycxmia and a con- (I953a) found little cedema in his autopsy series siderable increase both in pancreatic islet cell area could be explained by the infants having shed and in the insulin-secreting response to injected their fluid before death, and the first real challenge glucose. Under ideal conditions and in large to the popular ' waterlogged baby ' story came series they have a perinatal mortality rate which when we surprised ourselves by finding that in may be four times that for babies of normal the Edinburgh series the babies had not lost sig- women, and which even in good hospitals may be nificantly more weight than control infants during six or seven times greater than normal (Farquhar, the first week of life when they were matched as I958a).
    [Show full text]
  • A.Cicognani, L.Mazzanti*, O,Parisini*, A.Pellacanix. 0.Tassinarix, P.Anendt*, K.-D.Kohnert* (1Ntrod.B~ R.Illig) V.Venturoli*, S.Sandri*, A.Foraboscox
    A.Cicognani, L.Mazzanti*, O,Parisini*, A.Pellacanix. 0.TassinariX, P.Anendt*, K.-D.Kohnert* (1ntrod.b~ R.Illig) V.Venturoli*, S.Sandri*, A.ForaboscoX. E.Cacciari. 164 Childrens Hospital, Humboldt University, Berlin and Central Institute of Diabetes, 2nd Pediatric Clinic, University of Bologna and Chair of Hystology Karlsburg, German Democratic Republic. and Eabryology. University of Modena. Italy. THE HYPERINSULINEMIC HYPOGLYCEMIA IN INFANTS DIFFERENCES IN GLUCOSE TOLERANCE IN TURNER'S SYNDROME DEPENDING ON AND CHILDREN. A STUDY ON 9 CASES. AGE. Carbohydrate homeostasis was evaluated in 41 Turner-syndrose (aean age 11.5: Circulating levels of blood glucose, immunoreactive 2.7, range 5-16yrs) and in 25 short normal girls (mean age 10.8+2.1. range 6-16 insulin (IRI) and C-peptide immunoreactivity (CPR) were measured in 6 infants (4 had islet cell adenoma yrs) by means of OGTT. Impaired glucose tolerance was present in 31.7% of and 2 had nesidioblastosis) and 3 children (all had patients and in 8% of controls (p (0.025). Mean glucose at 60' (P<0.05). 90' islet cell adenoma) with hyperinsulinemic hypoglyce- (p C 0.01). 120' (p L 0.05), glucose peak (p c 0.005). and the integrated curve mia. The ratio blood glucose : insulin on several (p C0.005) were significantly higher in the patients. Mean insulin levels uere days had high value for diagnosis of hyperinsulinemic louer than in controls and the difference was significant at 30' (pd0.05)and for hypoglycemia. The oral glucose load gave variable re- the mean peak (p (0.05). The insulinogenic index was louer in the patients sults, and the arginine infusion was without abnorma- lity of hormone secretion.
    [Show full text]